Apart from the above 3 public offers, the Street will see as many 11 listings including that of Allied Blenders and Vraj Iron and Steel, wh...

Since Gennova has the manufacturing-at-risk approval, it has already produced 7 million doses that have been released not only by the compa...

In a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients a...

The IPO will consist of a primary issue and offer for sale from its promoter Satish Mehta and existing investor Bain Capital which acquired...

MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...

Emcure may appoint as many as six bankers for the IPO including JM Financial, Kotak Capital, Axis Capital and SBI Capital, the people said....

Eribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.

Among other listed stocks out of the five, Cadila Healthcare gained 2.87 per cent at Rs 512 at around the same time.

The new lawsuit has also named some individual executives, including Rajiv Malik, president of Mylan, and Satish Mehta, MD of Emcure Pharma.

Alkem Laboratories filed draft papers with capital markets regulator Sebi to raise an estimated Rs 1,500-3,500 crore through an IPO.

At end of trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 per cent and Ranbaxy Laboratories closed at Rs 819.55 apiece, ...

Sun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.

The central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...

This clears the way for creating the biggest drug company in India with a market share of 9% and the fifth largest generic drug firm in the...

With Indian drug makers flooding the developed markets, GSK, Merck, Pfizer now prefer tie-ups over acquisitions with Indian players.

The US drug regulator has inspected the manufacturing plants of at least half-a-dozen Indian drugmakers, raising hopes that these companies...

The government has banned manufacturing and sale of anti-obesity medicine Sibutramine and its combination drugs sold under various brands d...